Acadia Pharmaceuticals Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Acadia Pharmaceuticals Inc 's ROA in the third quarter of 2026?
Acadia Pharmaceuticals Inc achieved a return on average assets (ROA) of 21.6 % in its third quarter of 2026, this is above ACAD's average return on assets of -30.71%.
Acadia Pharmaceuticals Inc assets over the 12 months ending in its third quarter of 2026 are valued at $1,677 million

ROA fell compared to the second quarter of 2026, despite the net income growth of 69.92% from the second quarter of 2026.

However, within the Healthcare sector 44 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 149, from total ROA ranking in the second quarter of 2026 at 150.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	34.82 %	42.21 %	41.76 %	24.39 %	43.74 %
Y / Y Net Income Change	-25.43 %	18.13 %	-80.84 %	90.32 %	119.07 %
Net Income (TTM) in million	362	380	376	391	261
Return On Assets (TTM)	21.6 %	24.38 %	26.24 %	29.77 %	21.12 %
ACAD's Total Ranking	# 149	# 150	# 216	# 241	# 206
Total Assets (TTM) in million	1,794	1,743	1,605	1,564	1,331
Seq. Total Assets Change	2.94 %	8.58 %	2.62 %	17.54 %	8.59 %
Seq. Net Income Change	69.92 %	766.1 %	-98.67 %	281.13 %	169.18 %

ACAD's 5 Years Annual ROA >> Back to ACAD Management Effectiveness >> Compare ACAD ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 24
Sector	# 45
Overall	# 201

Return On Assets Statistics
High	Average	Low
29.77 %	-30.71 %	-75.5 %
(Dec 31 2025)		(Sep 30 2018)

Financial Statements
Acadia Pharmaceuticals Inc 's Assets	$ 1,794 million	ACAD's Balance sheet
Acadia Pharmaceuticals Inc 's Income	$ 54 million	Quarterly ACAD's Income Statement
ACAD's Income by Division		See ACAD's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	30.49 %	81.4 %	31.3 %	-17.23 %	-12.73 %
Total Assets in million	1,641	1,257	693	528	638
Y / Y Net Income Change	72.66 %	-	-	-	-
Net Income in million	391	226	-61	-216	-168
Annual Return On Assets	23.83 %	18.01 %	-8.84 %	-40.91 %	-26.32 %

ACAD's 5 Years Annual ROA >> Back to ACAD Management Effectiveness >> Compare ACAD ROA to its Competitors

Comment on ACAD's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 23.83 % compared to prior year, due to annual net income growth of 72.66 % to $391.00 million, while value of Acadia Pharmaceuticals Inc 's overall assets grew just by 30.49 % to $1,640.90 million, compared to $1,640.90 a year before.

More Return On Assets Ratios
ACAD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACAD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACAD's Competitors
Subscribers only: Roa for Acadia Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ACAD's Customers

You may also want to know
ACAD's Roi	ACAD's Inventory Turnover Ratio	ACAD's Growth Rates	ACAD's Dividend Comparisons
	ACAD's Profitability Ratios	ACAD's Asset Turnover Ratio	ACAD's Dividend Growth
ACAD's Roe	ACAD's Valuation Ratios	ACAD's Financial Strength Ratios	ACAD's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %

Date modified: 2026-11-09T06:44:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.